Development of a cancer-based chronic inhalation reference value for hexavalent chromium based on a nonlinear-threshold carcinogenic assessment

Regulatory Toxicology and Pharmacology

Volumn 64, Issue 3, 1970, Pages 466-480

  Haney, Joseph T ^a   Erraguntla, Neeraja ^a   Sielken, Robert L ^b   Valdez Flores, Ciriaco ^b  

^a Texas Commission on Environmental Quality (TCEQ)   (United States)

^b Sielken & Associates Inc   (United States)

Author keywords

Cancer; Carcinogenicity; Chromium; Hexavalent; Inhalation; Lung; Nonlinear; Risk; Threshold; Toxicity

Indexed keywords

CHROMIUM; HEXAVALENT CHROMIUM; UNCLASSIFIED DRUG; CARCINOGEN; CHROMIUM HEXAVALENT ION;

AIR POLLUTION; ARTICLE; CANCER RISK; CARCINOGENICITY; DISEASE COURSE; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; EVALUATION STUDY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; SCIENTIFIC LITERATURE; TOXIC INHALATION; ANIMAL; CHEMICALLY INDUCED DISORDER; EXPOSURE; LUNG TUMOR; METHODOLOGY; REVIEW; RISK ASSESSMENT;

ANIMALS; CARCINOGENS, ENVIRONMENTAL; CHROMIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INHALATION EXPOSURE; LUNG NEOPLASMS; REFERENCE VALUES; RISK ASSESSMENT;

EID: 84868495465     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.10.008     Document Type: Article

References (60)

1. American Cancer Society, 2012. Cancer facts and figures. Available at < http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf> (accessed April 2012).
2. Applied Epidemiology, 2002. Collaborative cohort mortality study of four chromate production facilities, 1958–1998: Final report. Prepared for the Industrial Health Foundation, Inc., September 27, 2002. OSHA Docket H054A Ex. 48–1-2.
3. ATSDR, 2008. Draft toxicological profile for chromium. Place Published: Agency for Toxic Substances and Disease Registry. < http://www.atsdr.cdc.gov/toxprofiles/tp7.pdf> (accessed March 2012).
4. Baetjer, A.M., Lowney, J.F., Steffee, H., et al. Effect of chromium on incidence of lung tumors in mice and rats. Arch. Ind. Health 20 (1959), 124–135.
5. Birk, T., Mundt, K., Dell, L., et al. Lung cancer mortality in the German chromate industry, 1958–1998. J. Occup. Environ. Med. 48:4 (2006), 426–433.
6. Bragt, P.C., van Dura, E.A., Toxicokinetics of hexavalent chromium in the rat after intratracheal administration of chromates of different solubilities. Ann. Occup. Hyg. 27:3 (1983), 315–322.
7. Brain, J.D., Proctor, D.F., Reid, L.M., (eds.) Respiratory Defense Mechanisms, 1977, Marcel Dekker, New York.
8. Brain, J.D., Sorokin, S.P., Godleski, J.J., Quantification, origin and fate of pulmonary macrophages. Brain, J.D., Proctor, D.R., Reid, L.M., (eds.) Respiratory Defense Mechanisms, Part II, 1977, Marcel Dekker, New York.
9. Cantin, A.M., North, S.L., Hubbard, R.C., et al. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 63:1 (1987), 152–157.
10. Cantin, A.M., Fells, G.A., Hubbard, R.C., et al. Antioxidant macromolecules in the epithelial lining fluid of the normal lower respiratory tract. J. Clin. Invest. 86 (1990), 962–971.
11. CIIT, 2004. Multiple path particle dosimetry model (MPPD v 2.0): a model for human and rat airway particle dosimetry: Centers for Health Research (CIIT) and National Institute for Public Health and the Environment (RIVM).
12. Crapo, J.D., Barry, B.E., Gehr, P., et al. Cell number and cell characteristics of the normal human lung. Am. Rev. Respir. Dis. 126:2 (1982), 332–337.
13. Cross, C.E., van der Vliet, A., O'Neill, C.A., et al. Oxidants, antioxidants, and respiratory tract lining fluids. Environ. Health Perspect. 102:Suppl. 10 (1994), 185–191.
14. Crump, K.S., Use of threshold and mode of action in risk assessment. Crit. Rev. Toxicol. 41:8 (2011), 637–650.
15. Crump, C., Crump, K., Hack, E., et al. Dose-response and risk-assessment of airborne hexavalent chromium and lung cancer mortality. Risk Anal. 23:6 (2003), 1147–1163.
16. Forschungsgemeinschaft, Deutsche, Alkali chromates(CrVI). Henschler, D., Lehnert, G., (eds.) Biological Exposure Values for Occupational Toxicants and Carcinogens: Critical Data Evaluation for BAT and EKA Values, 1994, VCH Verlagsgesellschaft, Weinhein, Germany.
17. De Flora, S., Petruzelli, S., Camoirano, A., et al. Pulmonary metabolism of mutagens and its relationship with lung cancer and smoking habits. Cancer Res. 47 (1987), 4740–4745.
18. De Flora, S., Camoirana, A., Bagnasco, M., et al. Estimates of the chromium(VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity. Carcinogenesis 18:3 (1997), 531–537.
19. De Flora, S., Threshold mechanisms and site specificity in chromium(VI) carcinogenesis. Carcinogenesis 21:4 (2000), 533–541.
20. Exponent, 2002a. Reanalysis of lung cancer mortality study for workers in the Baltimore chromium production facility. Prepared for the Chromium Coalition, November 2002. OSHA Docket H054A Ex. 31–18-15-1.
21. Exponent, 2002b. Critique of two studies by Gibb et al. Prepared for the Chromium Coalition, June 2002.
22. Fels, A.O., Cohn, Z.A., The alveolar macrophage. J. Appl. Physiol. 60 (1986), 353–369.
23. Glaser, U., Hochrainer, D., Kloppel, H., et al. Carcinogenicity of sodium dichromate and chromium(VI/III) oxide aerosols inhaled by male Wistar rats. Toxicology 42 (1986), 219–232.
24. Glaser, U., Hochrainer, D., Oldiges, H., Investigations of the lung carcinogenic potentials of sodium dichromate and Cr VI/III oxide aerosols in Wistar rats. Environ. Hyg. 1 (1988), 111–116.
25. Green, G.M., Jakab, G.J., Low, R.B., et al. Defense mechanisms of the respiratory membrane. Am. Rev. Respir. Dis. 115:3 (1977), 479–514.
26. Holmes, A.L., Wise, S.S., Wise, J.P., Carcinogenicity of hexavalent chromium. Indian J. Med. Res. 128 (2008), 353–372.
27. IARC, 2012. Agents reviewed by the IARC monographs, volumes 1–99. International Agency for Research on Cancer, Lyon. < http://monographs.iarc.fr/ENG/Classification/index.php> (accessed March 2012).
28. Jones, R.E., Hexavalent chrome: threshold concept for carcinogenicity. Biomed. Environ. Sci. 3 (1990), 20–34.
29. Lee, K.P., Ulrich, C.E., Geil, R.G., et al. Inhalation toxicity of chromium dioxide dust to rats after two years exposure. Sci. Total Environ. 86 (1989), 83–108.
30. Luippold, R.S., Mundt, K.A., Austin, R.P., et al. Lung cancer mortality among chromate production workers. Occup. Environ. Med. 60:6 (2003), 451–457.
31. McCarroll, N., Keshava, N., Chen, J., et al. An evaluation of the mode of action framework for mutagenic carcinogens case study II: chromium(VI). Environ. Mol. Mutagen. 51:2 (2009), 89–111.
32. Miksche, L.W., Lewalter, J., Health surveillance and biological effect monitoring for chromium exposed workers. Regul. Toxicol. Pharmacol. 26 (1997), S94–S99.
33. Nettesheim, P., Hanna, M.G., Doherty, D.G., et al. Effect of calcium chromate dust, influenza virus, and 100 R whole-body X-radiation on lung tumor incidence in mice. J. Natl. Cancer Inst. 47:5 (1971), 1129–1144.
34. Nickens, K.P., Patierno, S.R., Ceryak, S., Chromium genotoxicity: a double-edged sword. Chem. Biol. Interact. 188 (2010), 276–288.
35. NTP, 2011. Report on carcinogens. Twelfth Edition. US Department of Health and Human Services, Public Health Service, National Toxicology Program. < http://ntp.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf> (accessed March 2012).
36. O'Brien, T.J., Ceryak, S., Patierno, S.R., Complexities of chromium carcinogenesis: role of cellular response, repair and recovery mechanisms. Mutat. Res. 533:1–2 (2003), 3–36.
37. OSHA, 2006. Occupational exposure to hexavalent chromium, final rule. Code of Federal Regulations. Occupational Safety and Health Administration (OSHA). 29 CFR 1910, 1915, et al. Available at < http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_id=18599&p_table=federal_register> (accessed June 2012). February 28, 2006.
38. Park, R.M., Bena, J.F., Stayner, L.T., et al. Hexavalent chromium and lung cancer in the chromate industry: a quantitive risk assessment. Risk Anal. 24:5 (2004), 1099–1108.
39. Park, R.M., Stayner, L.T., A search for thresholds and other nonlinearities in the relationship between hexavalent chromium and lung cancer. Risk Anal. 26:1 (2006), 79–88.
40. Petrilli, F.L., Camoirano, A., Bennicelli, C., et al. Specificity and inducibility of the metabolic reduction of chromium(VI) mutagenicity by subcellular fractions of rat tissues. Cancer Res. 45 (1985), 3179–3187.
41. Petrilli, F.L., Rossi, G.A., Camoirano, A., et al. Metabolic reduction of chromium by alveolar macrophages and its relationships to cigarette smoke. J. Clin. Invest. 77 (1986), 1917–1924.
42. Proctor, D.M., Panko, J.P., Liebig, E.W., et al. Workplace airborne hexavalent chromium concentrations for the Painesville, Ohio chromate production plant (1943–1971). Appl. Occup. Environ. Hyg. 18:6 (2003), 430–449.
43. 2 phase by mismatch repair. Nucl. Acids Res. 35:2 (2007), 465–476.
44. Rhomberg, L.R., Goodman, J.E., Haber, L.T., et al. Linear low-dose extrapolation for noncancer health effects is the exception, not the rule. Crit. Rev. Toxicol. 41:1 (2011), 1–19.
45. Steffee, C.H., Baetjer, A.M., Histopathologic effects of chromate chemicals. Arch. Environ. Health 11 (1965), 66–75.
46. Steinhoff, D., Gad, S.C., Hatfield, G.K., et al. Carcinogenicity studies with sodium dichromate in rats. Exp. Pathol. 30 (1986), 129–141.
47. Suzuki, Y., Reduction of hexavalent chromium by ascorbic acid in rat lung lavage fluid. Arch. Toxicol. 62 (1988), 116–122.
48. Suzuki, Y., Fukuda, K., Reduction of hexavalent chromium by ascorbic acid and glutathione with special reference to the rat lung. Arch. Toxicol. 64 (1990), 169–176.
49. TCEQ, 2006. Guidelines to develop effects screening levels, reference values, and unit risk factors. Chief Engineer's Office. RG-442: Texas Commission on Environmental Quality.
50. Thomas, E.D., Ramberg, R.E., Sale, G.E., et al. Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science 192 (1976), 1016–1018.
51. Thompson, C.M., Haws, L.C., Harris, M.A., et al. Application of the USEPA mode of action framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium. Toxicol. Sci. 119 (2011), 20–40.
52. Tukey, J., Ciminera, J., Heyse, J., Testing the statistical certainty of a response to increasing dose of a drug. Biometrics 41:1 (1985), 295–301.
53. USEPA, 1984. Health assessment document for chromium. EPA-600/8-83-014F. US Environmental Protection Agency, Environmental Criteria and Assessment Office, Washington, DC.
54. USEPA, Toxicological Review of Hexavalent Chromium in Support of Summary Information on the Integrated Risk Information System (IRIS). 1998, US Environmental Protection Agency, Washington, DC.
55. USEPA, 2005a. Guidelines for carcinogen risk assessment. EPA/630/P-03/001B. Risk Assessment Forum, Washington, DC.
56. USEPA, 2005b. Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. EPA/630/R-03/003F. Risk Assessment Forum, Washington, DC.
57. USEPA, 2010. Toxicological review of hexavalent chromium in support of summary information on the Integrated Risk Information System (IRIS). EPA/635/R-10/004A. US Environmental Protection Agency, Washington, DC.
58. Xie, H., Wise, S.S., Wise, J.P. Sr., et al. Deficient repair of particulate hexavalent chromium-induced DNA double strand breaks leads to neoplastic transformation. Mutat. Res. 649:1–2 (2008), 230–238.
59. Zhitkovich, A., Chromium in drinking water: sources, metabolism, and cancer risks. Chem. Res. Toxicol. 24:10 (2011), 1617–1629.
60. Zuo, Z., Cai, T., Li, J., et al. Hexavalent chromium Cr(VI) up-regulates COX-2 expression through an NFκB/c-Jun/AP-1–dependent pathway. Environ. Health Perspect. 120:4 (2012), 547–553.